戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 pment, abnormal extrapyramidal movements and nephrosis.
2 ular damage and podocyte loss induced by PAN nephrosis.
3 ith histopathological findings of congenital nephrosis.
4  response to puromycin aminonucleoside (PAN) nephrosis.
5 function in a rat model of puromycin-induced nephrosis.
6 ween these processes in rats with adriamycin nephrosis.
7 ause of loss of renal function in adriamycin nephrosis.
8 induction of puromycin aminonucleoside (PAN) nephrosis.
9 se-activated receptor-specific manner during nephrosis.
10 lointerstitial nephritis associated with PAN nephrosis.
11 uria and how it causes the other findings of nephrosis.
12  that transcript levels of the podocyte gene nephrosis 2 homolog (Nphs2), were heritable and controll
13 5.15) for nephritis, nephrotic syndrome, and nephrosis; 4.08 (1.38-12.08) for esophageal cancer; 4.19
14 dence of proteinuria, indicated by relapsing nephrosis after CsA withdrawal, required additional cour
15  Most aging rats display chronic progressive nephrosis, although the rate at which injury develops is
16                                              Nephrosis and a rapid decline in kidney function charact
17 mbranous nephropathy who exhibited relapsing nephrosis and chronic depression of GFR.
18 in 1 (RIP1) kinase domain, prevented osmotic nephrosis and CIAKI, whereas an inactive Nec-1 derivate
19 linical CIAKI, including RCM-induced osmotic nephrosis and increased serum levels of urea and creatin
20 In the human glomerulopathies minimal-change nephrosis and membranous nephropathy, there is an increa
21  Developments related to the pathogenesis of nephrosis and why some patients develop focal segmental
22 a as a contributor to podocyte injury during nephrosis, and suggest that thrombin and/or podocyte-exp
23                           Some patients have nephrosis-associated renal disease characterized by typi
24 ncer, diabetes, nephritis/nephrotic syndrome/nephrosis, chronic lower respiratory disease, and influe
25  and function in rats with puromycin-induced nephrosis compared with that in animals with renal damag
26 he podocytes, leading to the hypothesis that nephrosis develops from an inability to develop a functi
27 assification systems that are used for hydro-nephrosis grading in ultrasound, for reflux and scar det
28 d tubulointerstitial injury in 86%, cholemic nephrosis in 29%, and glomerular changes in 38%.
29 n GBM contributes to the renal pathology and nephrosis in NPS.
30                                          PAN nephrosis increased the protein levels of JAM-A, occludi
31 t the induction of puromycin aminonucleoside nephrosis involves podocyte migration conducted by a coo
32      Puromycin aminonucleoside (PAN)-induced nephrosis is a well-described model of human idiopathic
33 d glomerulopathies, including minimal change nephrosis, membranous glomerulonephritis, and IgA nephro
34 he nephrotic syndrome, the murine adriamycin nephrosis model was used to explore the role of RAGE in
35 rthermore, the rat puromycin aminonucleoside nephrosis model, previously suspected of undergoing SD-T
36 glomerular basement membrane seen in the PAN nephrosis model.
37  with hirudin reduced proteinuria in two rat nephrosis models, and thrombin colocalized with a podocy
38  the candidate region for Finnish congenital nephrosis (NPHS1) in 19q13.1.
39                 In puromycin aminonucleoside nephrosis (PAN), GIV expression increased, GIV was phosp
40 nt to puromycin aminonucleoside (PA)-induced nephrosis (PAN), Podxl(+/-) mice are highly sensitive an
41 nephritis and puromycin aminonucleoside (PA) nephrosis rat models of podocyte injury.
42 d disorder characterized by microcephaly and nephrosis resulting from mutations in the WDR73 gene.
43 y, serologic, and histopathologic indices of nephrosis showed reversal of CG in 8 of 12 CYC202-treate
44 lasma thrombin generation is enhanced during nephrosis, suggesting that thrombin may contribute to ne
45                                         With nephrosis, there were comparable (greater than twofold)
46                                     Cholemic nephrosis was described in 1861 by Friedrich Frerichs, a
47                    The diagnosis of "osmotic nephrosis" was confirmed by renal biopsy, and the condit
48 ved glomerulonephritis (ICGN) mouse model of nephrosis, we examined the effects of dihydro-CDDO-trifl
49  Wistar albino rat shows progressive chronic nephrosis with age and therefore was used to determine t